Loutfy M - Search Results

1

The Use of Multistate Models to Examine Associations of Stress and Adherence With Transitions Among HIV Care States Observed in a Clinical HIV Cohort.

Blitz S, Antoniou T, Burchell A, Walmsley S, Light L, Gardner S, Rourke S, Cooper C, Kendall C, Loutfy M, Rachlis A, Wobeser W, Benoit A, Raboud J. Blitz S, et al. Among authors: loutfy m. J Acquir Immune Defic Syndr. 2017 Nov 1;76(3):303-310. doi: 10.1097/QAI.0000000000001493. J Acquir Immune Defic Syndr. 2017. PMID: 28700406

2

Salvage antiretroviral therapy in HIV infection.

Loutfy MR, Walmsley SL. Loutfy MR, et al. Expert Opin Pharmacother. 2002 Feb;3(2):81-90. doi: 10.1517/14656566.3.2.81. Expert Opin Pharmacother. 2002. PMID: 11829722 Review.

3

Can structured treatment interruptions (STIs) be used as a strategy to decrease total drug requirements and toxicity in HIV infection?

Walmsley S, Loutfy M. Walmsley S, et al. Among authors: loutfy m. J Int Assoc Physicians AIDS Care (Chic). 2002 Summer;1(3):95-103. doi: 10.1177/154510970200100304. J Int Assoc Physicians AIDS Care (Chic). 2002. PMID: 12942682 Review.

4

Clinical impact of double protease inhibitor boosting with lopinavir/ritonavir and amprenavir as part of salvage antiretroviral therapy.

Loutfy M, Raboud J, Thompson C, Tseng A, Abdurrahman Z, Kovacs C, Rachlis A, Phillips E, Rubin G, Gough K, Walmsley S. Loutfy M, et al. HIV Clin Trials. 2003 Sep-Oct;4(5):301-10. doi: 10.1310/7LYW-GQFF-WPRQ-K3QW. HIV Clin Trials. 2003. PMID: 14583846

5

Treatment of HIV infection in pregnant women: antiretroviral management options.

Loutfy MR, Walmsley SL. Loutfy MR, et al. Drugs. 2004;64(5):471-88. doi: 10.2165/00003495-200464050-00002. Drugs. 2004. PMID: 14977385 Review.

6

Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens.

Loutfy MR, Raboud JM, Walmsley SL, Saskin R, Montaner JS, Hogg RS, Thompson CA, Harrigan PR. Loutfy MR, et al. Antivir Ther. 2004 Aug;9(4):595-602. Antivir Ther. 2004. PMID: 15456091

7

Impact of acid-suppressive therapy on virologic response to atazanavir-based regimens in antiretroviral-experienced patients: a case series.

Antoniou T, Yoong D, Beique L, Chirhin S, Rachlis A, Gough K, Loutfy MR. Antoniou T, et al. J Acquir Immune Defic Syndr. 2005 May 1;39(1):126-8. doi: 10.1097/01.qai.0000160518.12957.c0. J Acquir Immune Defic Syndr. 2005. PMID: 15851924 No abstract available.

8

CD4(+) cell count increase predicts clinical benefits in patients with advanced HIV disease and persistent viremia after 1 year of combination antiretroviral therapy.

Loutfy MR, Walmsley SL, Mullin CM, Perez G, Neaton JD; Terry Beirn Community Programs for Clinical Research on AIDS; Canada HIV Trials Network. Loutfy MR, et al. J Infect Dis. 2005 Oct 15;192(8):1407-11. doi: 10.1086/466537. Epub 2005 Sep 9. J Infect Dis. 2005. PMID: 16170758

9

Physician perceptions and preferences in the treatment of acquired immunodeficiency syndrome (AIDS)-related lymphoma.

Cheung MC, Imrie KR, Leitch HA, Park-Wyllie LY, Buckstein R, Antoniou T, Loutfy MR. Cheung MC, et al. Ann Hematol. 2007 Sep;86(9):631-8. doi: 10.1007/s00277-007-0284-8. Epub 2007 Mar 20. Ann Hematol. 2007. PMID: 17372734

10

A prospective randomized controlled trial of structured treatment interruption in HIV-infected patients failing highly active antiretroviral therapy (Canadian HIV Trials Network Study 164).

Walmsley SL, Thorne A, Loutfy MR, LaPierre N, MacLeod J, Harrigan R, Trottier B, Conway B, Hay JR, Singer J, Zarowny D. Walmsley SL, et al. J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):418-25. doi: 10.1097/QAI.0b013e318061b611. J Acquir Immune Defic Syndr. 2007. PMID: 17468667 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

397 results

Search Page